Mobidiag Receives Emergency Use Authorization for its Automated COVID-19 Test in Finland

 Mobidiag Receives Emergency Use Authorization for its Automated COVID-19 Test in Finland

Mobidiag Receives Emergency Use Authorization for its Automated COVID-19 Test in Finland

Shots: Shots:

  • The company receives EUA for its Novodiag COVID-19 molecular diagnostic test used to detect SARS-CoV-2 virus rapidly and is now available in Finland and under process for obtaining EUA in Sweden, UK and France
  • The Novodiag COVID-19 assay qualitatively detects SARS-CoV-2 (orf1ab and N genes) directly from nasopharyngeal swabs and will operate using the Novodiag rapid ‘sample-in, result-out’ system, allowing the fully automated detection of COVID-19 in ~1hr.
  • The new test complements the emergency use test, Amplidiag COVID-19, suitable for high-throughput screening and was launched on Apr 14, 2020, with its availability in Finland and France

Click here ­to­ read full press release/ article | Ref: Mobidiag | Image: Mobidiag 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post